GenSight Biologics (SIGHT.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SIGHT.PA · Stock Price

EUR 0.08-0.01 (-7.49%)

Market Cap: $22.1M

Historical price data

Market Cap: $22.1MPipeline: 3 drugs (3 Phase 3)Founded: 2012Employees: 16HQ: Paris, France

Sector Ranking#81 in Cell & Gene Therapy #188 in Biologics / Biosimilars

Overview

GenSight Biologics is a Paris-based gene therapy company focused on creating transformative treatments for severe inherited retinal and neurodegenerative diseases. Its mission is to translate advanced science into long-lasting, single-administration cures, with its most advanced candidate, Lumevoq (lenadogene nolparvovec), having completed Phase III trials for LHON. The company's strategy leverages two proprietary technology platforms—Mitochondrial Targeting Sequence (MTS) and an optogenetics system—to address unmet medical needs in ophthalmology and beyond, operating with a lean, experienced team to advance its pipeline.

OphthalmologyNeurodegenerative Diseases

Technology Platform

Two proprietary platforms: 1) Mitochondrial Targeting Sequence (MTS) for allotopic expression of mitochondrial genes to treat disorders like LHON; 2) An optogenetics platform combining AAV gene therapy (encoding channelrhodopsin) with wearable biomimetic goggles to restore light sensitivity in advanced retinal degeneration.

Pipeline

3

3 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
GS010	Optic, Atrophy, Hereditary, Leber	Phase 3
GS010	Optic, Atrophy, Hereditary, Leber	Phase 3
Placebo	Leber Hereditary Optic Neuropathy	Phase 3

Funding History

3

Total raised:$180M

IPO$80MUndisclosedJun 15, 2018

Series B$60MUndisclosedJun 15, 2016

Series A$40MUndisclosedJun 15, 2014

Opportunities

A clear regulatory pathway and partnership for Lumevoq could unlock significant value in the near-term for a severe orphan disease.

Long-term, the GS030 optogenetics platform represents a groundbreaking, mutation-agnostic approach to end-stage blindness with potential applicability beyond RP.

Risk Factors

Severe financial constraints with a low market cap threaten the company's ability to fund ongoing operations and advance its pipeline.

The regulatory future of its lead asset, Lumevoq, remains uncertain, and its second program, GS030, carries high technical and clinical risk as a novel combination product.

Competitive Landscape

In LHON, Lumevoq's main competition is the symptomatic treatment Raxone, with other gene therapies in development. In optogenetics for RP, the field is nascent with few clinical competitors, but the approach competes conceptually with retinal implant devices. GenSight's platforms are highly differentiated but face validation hurdles.